Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PPM1D | O15297 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 2/20 | 0.30 |
| ▸ | MMP3 | P08254 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21389110 | 1.00 | LMNA (0.38) | LMNABRD4SMN1; SMN2APEX1BLM | |
| SCHEMBL28527501 | 1.00 | LMNA (0.38) | LMNABRD4SMN1; SMN2APEX1BLM | |
| SCHEMBL28522830 | 0.86 | APEX1 (0.35) | LMNASMN1; SMN2APEX1BLML3MBTL1 | |
| SCHEMBL28522829 | 0.86 | APEX1 (0.35) | LMNASMN1; SMN2APEX1BLML3MBTL1 | |
| SCHEMBL28532943 | 0.86 | APEX1 (0.35) | LMNASMN1; SMN2APEX1BLML3MBTL1 | |
| SCHEMBL35210460 | 0.80 | PPM1D (0.32) | SMN1; SMN2PPM1D | |
| SCHEMBL30752652 | 0.80 | PPM1D (0.32) | SMN1; SMN2PPM1D | |
| SCHEMBL24796281 | 0.80 | BRD4 (0.44) | LMNABRD4SMN1; SMN2APEX1BLM | |
| SCHEMBL21389171 | 0.80 | BRD4 (0.44) | LMNABRD4SMN1; SMN2APEX1BLM | |
| SCHEMBL28528640 | 0.80 | BRD4 (0.44) | LMNABRD4SMN1; SMN2APEX1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| CN-112236161-A | Modulators of G protein-coupled receptors | 卡莫特治疗学股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | LMNA 3629/4885BRD4 1415/4885SMN1; SMN2 2080/4885 |
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | LMNA 3907/4885BRD4 1441/4885SMN1; SMN2 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.